Expression of the proto-oncogene Axl in renal cell carcinoma

DNA and Cell Biology

Volumn 22, Issue 8, 2003, Pages 533-540

  Chung, Benjamin I ^c   Malkowicz, S Bruce ^a,b   Nguyen, Trang B ^b   Libertino, John A ^c   McGarvey, Terence W ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN AXL; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHEMOTAXIS; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LEUKEMOGENESIS; LUNG CANCER; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN VARIANT; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA STRUCTURE; RNA TRANSCRIPTION; STEADY STATE; STUDENT T TEST; TISSUE SECTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; GENE EXPRESSION; GENE SILENCING; HUMANS; KIDNEY; KIDNEY NEOPLASMS; ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 0141539416     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/10445490360708946     Document Type: Article

References (32)

1. AMIN, M.B., TAMBOLI, P., JAVIDAN, J., STRICKER, H., DE-PERALTA VENTURINA, M., DESHPANDE, A., and MENON, M. (2002). Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Sur. Path. 26, 281-291.
2. BELLOSTA, P., ZHANG, Q., GOFF, S.P., and BASILICO, C. (1997). Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15, 2387-2397.
3. BERCLAZ, G., ALTERMATT, H.J., ROHRBACH, V., KIEFFER, I., DREHER, E., and ANDRES, A.C. (2001). Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann. Oncol. 12, 819-824.
4. CHALLIER, C., UPHOFF, C.C., JANSSEN, J.W., and DREXLER, H.G. (1996). Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. Leukemia 10, 781-787.
5. DURIEZ, P.J., and SHAH, G.M. (1997). Cleavage of poly(ADP-ribose) polymerase: A sensitive parameter to study cell death. Biochem. Cell Biol. 75, 337-349.
6. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
7. FRIED, J., PEREZ, A.G., and CLARKSON, B.D. (1976). Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. J. Cell Biol. 71, 172-181.
8. GORUPPI, S., CHIARUTTINI, C., RUARO, M.E., VARNUM, B., and SCHNEIDER, C. (2001). Gas6 induces growth, beta-catenin stabilization, and T-cell factor transcriptional activation in contact-inhibited C57 Mammary Cells. Mol. Cell Biol. 21, 902-915.
9. GORUPPI, S., RUARO, E., and SCHNEIDER, C. (1996). Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12, 471-480.
10. GUNNINGHAM, S.P., CURRIE, M.J., HAN, C., TURNER, K., SCOTT, P.A., ROBINSON, B.A., HARRIS, A.L., and FOX, S.B. (2001). Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res. 61, 3206-3211.
11. HARBORTH, J., ELBASHIR, S.M., BECHERT, K., TUSCHL, T., and WEBER, K. (2001). Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 114, 4557-4565.
12. HORIKOSHI, T., DANENBERG, K., VOLKENANDT, M., STADLBAUER, T., and DANENBERG, P.V. (1993). Quantitative measurement of relative gene expression in human tumors. Meth. Mol. Biol. 15, 177-188.
13. JANSSEN, J.W., SCHULZ, A.S., STEENVOORDEN, A.C., SCHMIDBERGER, M., STREHL, S., AMBROS, P.F., BARTRAM, C.R. (1991). A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6, 2113-2120.
14. JEMAL, A., THOMAS, A., MURRAY, T., and THUN, M. (2002). Cancer statistics - 2002. CA Cancer J. for Clinicians 52, 23-47.
15. KONDO, K., YAO, M., YOSHIDA, M., KISHIDA, T., SHUIN, T., MIURA, T., MORIYAMA, M., KOBAYASHI, K., SAKAI, N., KANEKO, S., et al. (2002). Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34, 58-68.
16. LIN, W-C., LI, A.F-Y., CHI, C-W., CHUNG, W-W., HUANG, C.L., LUI, W-Y., KUNG, H-J., and WU, C-W. (1999). Tie-1 protein tyrosine: a novel independent prognostic marker for gastric cancer. Clin. Cancer Res. 5, 1745-1751.
17. McCLOSKEY, P., PIERCE, J., KOSKI, R.A., VARNUM, B., and LIU, E.T. (1994). Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ. 5, 1105-1117.
18. MERIC, F., LEE, W-P., SAHIN, A., ZHANG, H., KUNG, H-J., and HUNG, M-C. (2002). Expression profile of tyrosine kinases in breast cancer. Clin. Cancer Res. 8, 361-367.
19. NATALI, P.G., PRAT, M., NICOTRA, M.R., BIGOTTI A., OLIVERO, M., CORNOGLIO, P.M., DIRENZO, M.F. (1996). Overexpression of the met/HGF receptor in renal cell carcinomas. Int. J. Cancer 69, 212-217.
20. O'BRYAN, J.P., FRIDELL, Y-W., KOSKI, R., VARNUM, B., and LIU, E.T. (1995). The transforming receptor tyrosine kinase, axl, is post-translationally regulated by proteolytic cleavage. J. Biol. Chem. 270, 551-557.
21. O'BRYAN, J.P., FRYE, R.A., COGSWELL, P.C., NEUBAUER, A., KITCH, B., PROKOP, C., ESPINOSA, R., III, LE BEAU, M.M., EARP, H.S., and LIU, E.T. (1991). Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell Biol. 11, 5016-5031.
22. OKA, H., CHATANI, Y., HOSHINO, R., OGAWA, O., KAKEHI, Y., TERACHI, T., OKADA, Y., KAWAICHI, M., KOHNO, M., and YOSHIDA, O. (1995). Constitutive activation of mitogen activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55, 4182-4187.
23. ROCHLITZ, C., LOHRI, A., BACCHI, M., SCHMIDT, M., NAGEL, S., FOPP, M., FEY, M.F., HERRMANN, R., NEUBAUER, A. (1999). Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13, 1352-1358.
24. SCHMIDT, L., DUH, F.M., CHEN, F., KISHIDA, T., GLENN, G., CHOYKE, P., SCHERER, S.W., ZHUANG, Z., LUBENSKY, I., DEAN, M., et al. Germ-line and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73.
25. SCHULZ, A.S., SCHLEITHOFF, L., FAUST, M., BARTRAM, C.R., and JANSSEN, J.W. (1993). The genomic structure of the human UFO receptor. Oncogene 8, 509-513.
26. UHLMAN, D.L., NGUYEN, P., MANICEL, J.C., ZHANG, G., HAGAN, K., FRALEY, E., AEPPLI, D., and NIEHAUS, G.A. (1995). Epidermal growth factor and transforming growth factor alpha expression in papillary and non-papillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer Res. 1, 913-920.
27. VARNUM, B.C., YOUNG, C., ELLIOTT, G., GARCIA, A., BARTLEY, T.D., FRIDELL, Y.W., HUNT, R.W., TRAIL, G., CLOGSTON, C., TOSO, R.J. (1995). Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373, 623-626.
28. WIMMEL, A., GLITZ, D., KRAUS, A., ROEDER, J., and SCHUERMANN, M. (2001). Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur. J. Cancer 37, 2264-2274.
29. WOODWARD, E.R., CLIFFORD, S.C., ASTUTI, D., AFFARA, N.A., and MAHER, E.R. (2002). Familial clear cell renal cell carcinoma (RCRC): Clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J. Med. Genet. 37, 348-353.
30. YANAGITA, M., ARAI, H., ISHII, K., NAKANO, T., OHASHI, K., MIZUNO, K., VARNUM, B., FUUKATSU, A., DOI, T., and KITA, T. (2001a). Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am. J. Pathol. 158, 1423-1432.
31. YANAGITA, M., ARAI, H., NAKANO, T., OHASHI, K., MIZUNO, K., FUKATSU, A., DOI, T., and KITA, T. (2001b). Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J. Biol. Chem. 276, 42364-42369.
32. YANAGITA, M., ISHII, K., OZAKI, H., ARAI, H., NAKANO, T., OHASHI, K., MIZANO, K., KITA, T., and DOI, T. (1999). Mechanism of inhibitory effect of warfarin on mesangial cell proliferation. J. Am. Soc. Nephrol. 10, 2503-2509.